Black Diamond Therapeutics (BDTX) Interest & Investment Income (2019 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Interest & Investment Income came in at $1.0 million in Q1 2026, up 71.93% YoY from $595000.0 in Q1 2025, and down 13.6% on a QoQ basis from $1.2 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Interest & Investment Income (2019 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 8 years of Interest & Investment Income data on file, last reported at $1.0 million in Q1 2026.
- Quarterly Interest & Investment Income rose 71.93% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (up 109.77% YoY) and the FY2025 annual result came in at $4.1 million, up 86.11% from the prior year.
- Interest & Investment Income fell to $1.0 million in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $1.2 million in Q4 2025 to a low of $324000.0 in Q4 2023.
- A 5-year average of $660058.8 and a median of $565000.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income tumbled 64.76% — and 2025, when it soared 140.95%.
- Tracing BDTX's Interest & Investment Income over 5 years: stood at $677000.0 in 2022, then slumped by 52.14% to $324000.0 in 2023, then surged by 74.38% to $565000.0 in 2024, then jumped by 109.56% to $1.2 million in 2025, then retreated by 13.6% to $1.0 million in 2026.
- The last three Interest & Investment Income figures came in at $1.0 million (Q1 2026), $1.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | 922,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 922,000.00 |
| Mar 31, 2026 | 1.02 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 1.12 Mn |
| Mar 31, 2025 | 595,000.00 |
| Dec 31, 2024 | 565,000.00 |
| Sep 30, 2024 | 516,000.00 |
| Jun 30, 2024 | 464,000.00 |
| Mar 31, 2024 | 637,000.00 |
| Dec 31, 2023 | 324,000.00 |
| Sep 30, 2023 | 439,000.00 |
| Jun 30, 2023 | 539,000.00 |
| Mar 31, 2023 | 622,000.00 |
| Dec 31, 2022 | 677,000.00 |
| Sep 30, 2022 | 562,000.00 |
| Jun 30, 2022 | 386,000.00 |
| Mar 31, 2022 | 406,000.00 |
| Dec 31, 2021 | 588,000.00 |
| Sep 30, 2021 | 776,000.00 |